Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia

Trial Profile

Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2017

At a glance

  • Drugs Golimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms Go-Compl-Ar
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Feb 2017 Status changed from recruiting to discontinued.
    • 21 Dec 2016 Planned End Date changed from 1 Feb 2019 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top